Product Information
TRIAMCINOLONE 0.025% OINT is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.0740 per GM under NDC 45802005436. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AT.
Strength
.25 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802005436
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
TRIAMCINOLONE ACETONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA087385FDA Approved
Before 1982
TE Code
AT
On Market Since
5/12/2006
Pharmacological Classes
Price Statistics
The NADAC for TRIAMCINOLONE 0.025% OINT has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 9.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0740 per GM |
|---|---|
| All-time high | $0.0882 (Oct 11, 2017) |
| All-time low | $0.0569 (May 22, 2024) |
| 52-week high | $0.0764 |
| 52-week low | $0.0724 |
| Median price | $0.0768 |
| Average price | $0.0769 |
| Largest weekly change | +38.5% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Triamcinolone Acetonide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Triamcinolone Acetonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAMCINOLONE 0.025% OINT?
The current National Average Drug Acquisition Cost (NADAC) for TRIAMCINOLONE 0.025% OINT, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.0740 per GM (NDC 45802005436), effective Sep 30, 2026.
How has the price of TRIAMCINOLONE 0.025% OINT changed over time?
Over the history we have for it, the NADAC for TRIAMCINOLONE 0.025% OINT has declined 9.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRIAMCINOLONE 0.025% OINT?
Since Nov 28, 2013, the NADAC for TRIAMCINOLONE 0.025% OINT has ranged from a low of $0.0569 (May 22, 2024) to a high of $0.0882 (Oct 11, 2017), with a median of $0.0768 per GM.
Are there cheaper alternatives to TRIAMCINOLONE 0.025% OINT?
No other NADAC-published product currently shares the active ingredient and strength of TRIAMCINOLONE 0.025% OINT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRIAMCINOLONE 0.025% OINT?
TRIAMCINOLONE 0.025% OINT (NDC 45802005436) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.